Laddar...
Citalopram for agitation in Alzheimer’s disease (CitAD): design and methods
BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer’s disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer’s disease...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2012
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3333484/ https://ncbi.nlm.nih.gov/pubmed/22301195 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2011.01.007 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|